Healthcare Brand Affinity Index — Measuring Brand Strength via Competitive Data
What traditional brand measurement captures (and misses)
Traditional healthcare brand metrics:
- NPS surveys — capture patient sentiment at survey moment
- Unaided recall — measures top-of-mind awareness
- Brand consideration — patients including brand in initial set
- Brand share-of-voice — share in unprompted patient discussion
These work — but they capture perception, not the operational signals that reveal underlying brand strength. A brand can have moderate NPS but still be operationally weak (relying on discount escalation), or have lower NPS but operationally strong (ads run 200+ days, no discount pressure).
The 5 operational signals of brand strength
Signal 1: Ad longevity
Brands with strong audience affinity run ads 60-90+ days without fatigue. Brands with weak affinity see ads die in 14-21 days. Across Prism Spy data, ad longevity correlates with brand strength at r=0.58.
Signal 2: Hook stability
Strong brands maintain core hook positioning over 6-12 months. Weak brands rotate hooks every 4-8 weeks (signal of finding what works). Hook diversity is healthy when intentional; chaos when forced.
Signal 3: Creative reuse rate
Strong brands can repurpose creative assets across multiple markets (city, demographic, format) — the asset works because the brand foundation is solid. Weak brands need bespoke creative per market segment.
Signal 4: Offer differentiation discipline
Strong brands maintain premium offer positioning without discount escalation. Weak brands ratchet discount intensity 3-5% per quarter — visible signal of price-led acquisition.
Signal 5: Share-of-voice resilience
Strong brands maintain share-of-voice during competitive escalations. Weak brands lose 15-30% share-of-voice when a competitor enters aggressively.
The composite Brand Affinity Index (0-100)
Each signal scored 0-20:
- 0-20: Ad Longevity score (% of ads running >60 days)
- 0-20: Hook Stability score (consistency of top 3 hooks over 6 months)
- 0-20: Creative Reuse score (% of creatives running in 3+ markets)
- 0-20: Offer Discipline score (inverse of discount escalation rate)
- 0-20: Share-of-Voice Resilience (variance under competitive pressure)
Total 0-100. Quarterly tracked. Trend over time more meaningful than point-in-time score.
Index interpretation
- 80-100: Premium brand. Ad longevity, hook stability, no discount pressure. Operationally untouchable.
- 60-79: Strong brand. Some weakness, generally healthy. Common across top-quartile clinics.
- 40-59: Mid-tier. Mixed signals. Specific weaknesses to address (often offer discipline).
- 20-39: Weak brand. Multiple operational weaknesses. Brand rebuild needed, not more performance spend.
- 0-19: Brand crisis. Discount-led acquisition, short ad lifespans, no hook stability. Rebuild urgent.
Case study — same specialty, different brand strength
Anonymised IVF clinics in the same Tier-1 metro:
- Brand A — Affinity Index 82. Ads run 80+ days average. 3 core hooks stable for 9 months. No discount pressure. Resilient share-of-voice. Premium positioning sustained.
- Brand B — Affinity Index 45. Ads die at 18-25 days. Hooks rotate every 6-8 weeks. 15% discount escalation in last 12 months. Share-of-voice declining. Operationally weak despite similar Meta spend.
Brand A's CPL is 38% lower than Brand B's despite Brand B running more aggressive discounting. Operational discipline compounds.
How to use the Brand Affinity Index
- Quarterly internal tracking — your own index trajectory matters more than competitor comparison.
- Competitive benchmarking — annual comparison against same-specialty + same-city competitors.
- Investment allocation — high-Affinity brands should invest in scale + new markets; low-Affinity brands should invest in brand rebuild first.
- Pre-acquisition / pre-investment diligence — for healthcare investors, the Index surfaces operational brand strength that financial statements don't.
Get your Brand Affinity Index.
ICG runs a Prism Spy Brand Affinity audit on your brand — current 0-100 score, weakest signals, quarterly trend, competitor comparison. Founder-led by Rohit + Hanuman.
Book a free audit → WhatsApp ICGRelated reading
- Prism Spy product page
- ICG brand consulting service
- Discount intensity in healthcare
- How to spy on competitor Meta ads
Sources & methodology +
Primary data — ICG's live client portfolio (150+ healthcare brands, 12+ specialties, since 2018): CPQL, EMQ, lead-to-consult conversion, cohort MRR:CAC. All numbers are portfolio aggregates unless a specific client is named.
Platform data — Google Search Console (impressions, CTR, position), Google Analytics 4 (session behaviour, conversion paths), Meta Ads Manager (EMQ, CTWA, CAPI event quality), Google Ads (search terms, quality score, intent-tier classification), Angryturtle GBP portfolio (143 listings under management).
Regulatory sources — NMC Ethics Code 2026, DPDP Act 2023, ART (Regulation) Act 2021, NABH 6th Edition, ASCI Healthcare Guidelines — cited when the article references compliance obligations. Regulatory interpretations are current as of the article's last-updated date.
Third-party research — When cited, sources are named inline (Practo, PwC India Healthcare, McKinsey Life Sciences, etc.) with the publication year. If a stat has no citation, it comes from ICG's own portfolio.
Methodology transparency — See /about/methodology for the diagnostic framework used to produce these insights, and /editorial-standards for the fact-check + review workflow every published article goes through.
Got it, .
A founder will reach out within one business day. In the meantime — WhatsApp Rohit directly for the fastest reply.
💬 Message Rohit on WhatsApp
Hi, I'm Rohit. Co-Founder, ICG.
Right process, right systems, right ecosystem. If you're systems-driven and data-driven about your healthcare brand, let's talk. I reply personally.
Message Rohit on WhatsAppOr call: +91 81302 26224